Skip to main content

Table 1 Demographic and clinical characteristics of 159 HF patients

From: Impact of multi-disciplinary treatment strategy on systolic heart failure outcome

Variables HFDMP non-HFDMP χ2/t p
n/means %/std. n/means %/std.
Age 69.79 14.98 70.47 14.01 −0.29 .77
Gender      1.63 .20
 Male 59 62.11 46 71.88   
 Female 36 37.89 18 28.13   
peak VO2 14.07 3.32 17.50 2.12 −1.40 .18
VE/VCO2 at AT 39.92 6.46 33.00 0.00 1.47 .17
Mortality      1.01 .32
 Survival 84 88.42 53 82.81   
 Death 11 11.58 11 17.19   
LVEF 32.25 5.87 31.03 7.16 1.18 .24
Atrial Fibrillation      0.95a .81
 non AF 59 62.11 44 68.75   
 Paroxysmal AF 24 25.26 14 21.88   
 Persistent AF 3 3.16 1 1.56   
 Permanent AF 9 9.47 5 7.81   
Ischemic CM 56 58.95 36 56.25 0.11 .74
Hypertension 74 77.89 50 78.13 0.00 .97
Diabetes mellitus 44 46.32 24 37.50 1.21 .27
Hyperlipidemia 56 58.95 30 46.88 2.24 .13
Stroke 23 24.21 13 20.31 0.33 .56
Old MI 31 32.63 23 35.94 0.19 .67
PAD 16 16.84 8 12.50 0.56 .45
CKD 59 62.11 44 68.75 0.74 .39
PCI 36 37.89 23 35.94 0.06 .80
Medication / Treatment
 ACEI/ARB 76 80.00 49 76.56 0.27 .60
 β-blocker 62 65.26 40 62.50 0.13 .72
 Aldactone 38 40.00 19 29.69 1.77 .18
 Diuretics 74 77.89 48 75.00 0.18 .67
 Digoxin 17 17.89 5 7.81 3.26 .07
 ICD 12 12.63 1 1.56 6.24 .01
 CRT 7 7.37 4 6.25 0.07a 1.00
  1. Abbreviations: HFDMP heart failure disease management program, VE minute ventilation, AT anaerobic threshold, LVEF left ventricular ejection fraction, AF atrial fibrillation, CM cardiomyopathy, HF heart failure, MI myocardial infarction, PAD peripheral artery disease, CKD chronic kidney disease, PCI percutaneous coronary intervention, ACEI angiotensin converted enzyme inhibitor, ARB angiotensin receptor blocker, ICD implantable cardioverter defibrillator, CRT cardiac resynchronization therapy
  2. aFisher exact test